# Junta clínica — PT-pseudo_7bcbfa157137 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_7bcbfa157137",
  "pid": "PT-pseudo_7bcbfa157137",
  "task": 1,
  "psa": 7.4,
  "age": 69,
  "months": 1,
  "pirads": "4",
  "psad": 0.117,
  "psav": 1.55,
  "psap": 5.7,
  "vol": 63.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.83814454,
  "medhx": "Hypertension, Type 2 diabetes",
  "meds": "valsartan, lisinopril, metoprolol, metformin, empagliflozin",
  "notes": "PSA 7.4 ng/mL. PI-RADS 4. PSAD 0.12. Prostate volume 63 mL. csPCa 0.84.",
  "pmhx": [
    "Hypertension",
    "Type 2 diabetes"
  ],
  "allergies": [],
  "vitals": {
    "weight": "89 kg",
    "height": "186 cm",
    "bmi": "25.7",
    "bp": "124/77 mmHg",
    "hr": "69 bpm",
    "smoking": "Non-smoker",
    "last_dental": "1 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "31 Jan 2025",
  "enc_ref": "Dr. P. van Dijk (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment requested due to previous biopsy positivity alongside a continuous upward trend in PSA levels."
    },
    {
      "s": "History",
      "t": "This 69-year-old gentleman, married and residing with his partner, has recently stepped down from his role as a postal worker. He abstains from tobacco, walks approximately 45 minutes daily, and consumes around 13 units of alcohol weekly. His medical background includes hypertension and type 2 diabetes, currently regulated by valsartan, lisinopril, metoprolol, metformin, and empagliflozin, with recent cardiology parameters remaining stable. Urinary symptoms are negligible, reflected by an IPSS score of 1. Past surgical history encompasses a knee arthroscopy performed half a decade ago, and he occasionally experiences minor lower back stiffness following extended gardening, neither requiring specialist care. He previously opted out of research trials. Adenocarcinoma was confirmed on his earlier biopsy. He maintains full independence in daily activities and remains in good overall health."
    },
    {
      "s": "Physical examination",
      "t": "DRE: Examination is normal; the prostate exhibits a symmetrically enlarged contour with a smooth, firm texture, devoid of palpable asymmetry or discrete nodules. General assessment shows no abnormalities. Blood pressure registers at 124/77 mmHg, accompanied by a regular cardiac rhythm of 69 bpm. Abdominal palpation yields a soft, non-tender abdomen free of palpable masses or organ enlargement."
    }
  ],
  "occupation": "retired postal worker",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [],
  "alcohol": "13 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 1/35 (mild LUTS)",
  "admin": "Patient declined research participation previously; respect for AS-related trials.",
  "mri_hospital": "Antoni van Leeuwenhoek",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_7bcbfa157137
Task: 1

Encounter: Urology - outpatient on 31 Jan 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 69-year-old male
  - PSA: 7.4 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.117 ng/mL²
  - PSA velocity: 1.55 ng/mL/yr
  - Prior PSA: 5.7 ng/mL
  - Prostate volume: 63.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.83814454 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Type 2 diabetes
  - Problem list / PMHx: Hypertension, Type 2 diabetes
  - Current medication: valsartan, lisinopril, metoprolol, metformin, empagliflozin
  - Allergies: NKA
  - Additional notes: PSA 7.4 ng/mL. PI-RADS 4. PSAD 0.12. Prostate volume 63 mL. csPCa 0.84.

Vitals: weight 89 kg, height 186 cm, BMI 25.7, BP 124/77 mmHg, HR 69 bpm. Smoking: Non-smoker.

Chief complaint: Assessment requested due to previous biopsy positivity alongside a continuous upward trend in PSA levels.

History: This 69-year-old gentleman, married and residing with his partner, has recently stepped down from his role as a postal worker. He abstains from tobacco, walks approximately 45 minutes daily, and consumes around 13 units of alcohol weekly. His medical background includes hypertension and type 2 diabetes, currently regulated by valsartan, lisinopril, metoprolol, metformin, and empagliflozin, with recent cardiology parameters remaining stable. Urinary symptoms are negligible, reflected by an IPSS score of 1. Past surgical history encompasses a knee arthroscopy performed half a decade ago, and he occasionally experiences minor lower back stiffness following extended gardening, neither requiring specialist care. He previously opted out of research trials. Adenocarcinoma was confirmed on his earlier biopsy. He maintains full independence in daily activities and remains in good overall health.

Physical examination: DRE: Examination is normal; the prostate exhibits a symmetrically enlarged contour with a smooth, firm texture, devoid of palpable asymmetry or discrete nodules. General assessment shows no abnormalities. Blood pressure registers at 124/77 mmHg, accompanied by a regular cardiac rhythm of 69 bpm. Abdominal palpation yields a soft, non-tender abdomen free of palpable masses or organ enlargement.

Patient info: retired postal worker; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 13 units / week; exercise Walking 45 min/day; IPSS score: 1/35 (mild LUTS).


Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.47
  uncertainty  +/- 0.12 epistemic (95% band 0.23-0.70); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.75: PI-RADS 4, PSA 5.3, PSAD 0.092, age 65, DRE Normal -> BIOPSY (clear). He wrote: "P4 in 65 years old patient"
  2. distance 0.78: PI-RADS 4, PSA 6.5, PSAD 0.11, age 64, DRE Normal -> DEFER (uncertain). He wrote: "Need initial ISUP grade and MRI in men on active surveillance."
  3. distance 0.86: PI-RADS 4, PSA 4.5, PSAD 0.07, age 71, DRE Normal -> DEFER (clear). He wrote: "Man on active surveillance. MRI stabile and PSA moderately high."

PRECEDENT: DEFER (weighted vote 0.35 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that a stable MRI (PRECISE 1-3) with a low PSA-D (< 0.15) may lead to omitting a repeat biopsy in patients with low-risk disease. The guideline also suggests that a PSA change alone should not change management based on its weak link with grade progression.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your suggestion of no biopsy is not decisive because the guideline requires establishing the documented grade of the prior biopsy. EXPERT-COHORT, the cohort criterion is insufficient because the guideline emphasizes that the documented grade of the prior biopsy and surveillance history are what decide the decision, which is what the Registrar is tasked to find.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - whether the PSA has normalized: if the PSA has normalised, a new PSA test can be performed after one year
laboratory_results - whether the PSA-D is below 0.15ng/mL/cc: this is a factor in risk-adapted biopsy guidance

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges entirely on establishing the documented grade of the prior biopsy and the surveillance status detailed in the previous notes.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size or extraprostatic extension require re-sampling?
  psa_trend (get_psa_trend) -> Has the PSA normalized, which would allow for a repeat PSA test after one year?
  previous_notes (get_previous_notes) -> What is the documented grade of the prior biopsy, and is the patient on a surveillance protocol?
  laboratory_results (get_lab_results) -> Is the PSA density below 0.15 ng/mL/cc?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason/ISUP) of the prior biopsy?
  Q2. Is the documented grade of the prior biopsy ISUP 2 or above, according to the EAU guideline?
  Q3. Is the PSA density below 0.15 ng/mL/cc, according to the laboratory results?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: 14 mm hypointense focus within the right peripheral zone at the mid-gland level.

psa_trend
Has the PSA normalized, which would allow for a repeat PSA test after one year?
The PSA trend shows a rise from 2.2 (Feb 2022) to 7.4 (Jan 2025).

previous_notes
What is the documented grade of the prior biopsy, and is the patient on a surveillance protocol?
The documented grade of the prior biopsy is not explicitly stated, but the note mentions a "positive histological results" from a biopsy conducted earlier this year. The patient is not explicitly stated to be on a formal surveillance protocol with a confirmatory biopsy due.

laboratory_results
Is the PSA density below 0.15 ng/mL/cc?
The PSA density is 0.117 ng/mL/mL, which is below 0.15 ng/mL/cc.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes provided sufficient information regarding the prior biopsy status and surveillance.

WHAT THIS SUPPORTS
FOR sampling this patient now
PSA density is below 0.15 ng/mL/cc, which is a factor in risk-adapted biopsy guidance.
The documented grade of the prior biopsy is not explicitly stated, which leaves the indication standing according to EAU guidelines.

AGAINST sampling this patient now
The documented grade of the prior biopsy is not explicitly stated, which means the indication for re-biopsy is not definitively established.

WHERE THIS LEANS
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 7.40 ng/mL over 4 points spanning 35 months; velocity +2.00 ng/mL per year; doubling time about 18 months.
PROJECTION at 6 months: 8.8 ng/mL, conformal 95% band 2.5-30.8.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.65
  uncertainty  +/- 0.12 epistemic (95% band 0.42-0.89), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.47  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.65  ('supports' tier, fusion_full; weight 3.0)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.35  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.61 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-STRUCTURED, EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: borderline. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the Registrar appear to have addressed all three moderator questions, although the answer to Q1 (documented grade) remains explicitly unstated in the retrieved notes.

ALIGNMENT WITH THE PANEL
The panel protocol concluded with a BIOPSY recommendation based on a weighted vote, primarily driven by EXPERT-FUSION's high probability, despite the lack of a documented prior grade in the opened documents.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason/ISUP) of the prior biopsy? Answered: Not explicitly stated in the previous notes.
Q2. Is the documented grade of the prior biopsy ISUP 2 or above, according to the EAU guideline? Answered: Cannot be determined as the grade is not stated.
Q3. Is the PSA density below 0.15 ng/mL/cc, according to the laboratory results? Answered: Yes, the PSA density is 0.117 ng/mL/mL, which is below 0.15 ng/mL/cc.

WHAT CARRIES WEIGHT, AND WHY
The PSA density being below 0.15 ng/mL/cc is relevant because the EAU guideline suggests this is a factor in risk-adapted biopsy guidance. The lack of a documented prior biopsy grade is critical because the EAU guideline states that the documented grade determines the indication for re-biopsy.

MY SUGGESTION TO THE CHAIR
Given that the PSA density is favorable according to the laboratory results, but the documented prior biopsy grade is missing, the decision remains unclear according to the guideline. I suggest deferring until the documented grade is established.

VERDICT: not-ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

69y male, PSA 7.4, PI-RADS 4, prior positive biopsy grade unrecorded. Low PSA density (0.117) argues for observation, but the unrecorded prior grade necessitates sampling to determine management. Initial ISUP not recorded, making the decision to biopsy contingent on that missing data. Recommend biopsy for tissue characterization.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
